PharmTech News

Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.

Articles

Cornell researchers reveal that an existing FDA-approved drug can facilitate the delivery of other large molecules across the blood-brain barrier.

Researchers Discover a Method to Penetrate the Blood-Brain Barrier

Inflectra is the second biosimilar to hit the market in the United States.

FDA Approves First mAb Biosimilar

The companies announced that they have mutually decided to terminate the planned merger after the US Department of Treasury and the IRS issue temporary and proposed regulations on tax inversion.

Pfizer and Allergan Terminate Merger Agreement

Jack Lew, Obama’s secretary of the treasury, announced on April 4, 2016, that the US Department of the Treasury and the Internal Revenue Service (IRS) is issuing temporary and proposed regulations to limit the “benefits of and limit the number of corporate tax inversions.” The government bodies also plan to address earnings stripping in these inversions, so it will examine past inversion deals that have already been completed.

New Regulations Will Help the US Treasury Police Inversion Transactions

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Industry is joining with academia and global health leaders to examine new approaches to biotech manufacturing.

Biotech Manufacturers Explore Global Access and Supply Chain Hurdles

The taskforce will work to identify opportunities to advance therapy manufacturing and the supply chain in the UK.

MMIP Launches Advanced Therapy Manufacturing Taskforce

The studies, conducted across eight countries with nearly 600 inflammatory bowel disease (IBD) patients, further support claims by Celltrion that Remsima is highly similar its reference product.

Studies Demonstrate Remsima Efficacy and Safety Following Switch from Infliximab

During a clinical trial of 48 participants, 100% of those that received the TV003 vaccine were protected from infection.

NIH Investigational Dengue Vaccine Proves 100% Effective

Sir Andrew Witty, CEO of GlaxoSmithKline, has said that he plans to retire from the company in March 2017, after nearly ten 10 years in the position.

GSK CEO to Retire in March 2017

With a new name formed from the legacy company names, Alcami offers development services, analytical testing, and API and finished drug development and manufacturing.

Top News